The Global Alliance for Vaccines and Immunization said that thanks to increased demand for the pentavalent, or five-in-one vaccine and a reduced price offer by an un-named emerging market vaccine manufacturer, the average price will drop to $2.58 next year compared to the current average price of $2.97.
This represents a decrease of 30 percent over the last seven years, GAVI said in a statement.
The pentavalent vaccine, which protects against diphtheria, tetanus, pertussis, Haemophilus influenza type b (Hib), and hepatitis B, is routinely given to children in wealthy nations but price has kept it out of the reach of some poorer nations.
